Home » Topics » BioWorld Science

BioWorld Science
RSS

FDA clears IND for phase I/II MARINA study of AOC-1001

Aug. 3, 2021

Ascentage Pharma discovers mutant GTPase KRAS inhibitors

Aug. 3, 2021

New CDK and TRK inhibitors identified at Hangzhou Innogate Pharma

Aug. 3, 2021

Bristol Myers Squibb patents CD80/PD-L1 and/or PD-1/PD-L1 interaction inhibitors

Aug. 3, 2021

Hovione Scientia describes ligand drug conjugates including BET inhibitors

Aug. 3, 2021

Vaxart's IND application for S-only oral tablet COVID-19 vaccine cleared in U.S.

Aug. 3, 2021

First patient dosed in phase II study of ZN-c3 in uterine serous carcinoma

Aug. 3, 2021

U.K. MHRA clears initiation of first-in-human study of HMBD-001 in advanced cancers

Aug. 2, 2021

China NMPA accepts IND for phase I study of CAN-103 for Gaucher's disease

Aug. 2, 2021

Lundbeck opens phase I study of Lu-AG-09222 in headache model

Aug. 2, 2021

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...